他汀类药物在冠心病防治中的合理应用
摘要
实验已证明,血清胆固醇(TC),甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)的升高及高密度脂蛋白胆固醇(HDL-C)的降低是动脉粥样硬化、冠心病和脑血管疾病的重要致病因素,众多的临床试验证实,有效的调脂治疗不管作为心脑血管病的一级或二级预防治疗,都可明显降低心脑血管疾病的发生率和死亡率,改善冠心病患者介入治疗的预后[1][2].
出处
《首都医药》
2003年第22期35-38,共4页
Capital Medicine
参考文献15
-
1Pedersen TR.Coronary arery disease: The Scandinavian Simvastatin Survival Study experience. Am J Cardiol 1998,8 (10) :53-56.
-
2Smith SC,Blair SN. Ronow RO,et al. AHA/ACC quidelines for preventing heart attack and death in patients with atherosclerostic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.J Am Coll Cardiol 2001,38 (5) :1571-1583.
-
3Waters DD, Hsue PY. l.ow-density-lipoprotein cholesterol goals for patients with coronary disease treating between the lines Circulation.2001,104, 2631-2637.
-
4Export Panel on Detection, Evaluation,and Treatment of High Blood Cholesterol in Adults, Executive summary of third repot of the National cholesterol Education Program(NCEP)Expert panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults Treat-ment Panel (Ⅲ) JAMA 2001,285(19) :2486-2509.
-
5Ridker PM. Rapid reduction in C-reative protein with cerivastatin among 785 patients with primary hyperolesterolemia. Circulation 2001,3:1191-1193.
-
6Dupuis MD,Tardif MD, Cemacek MD, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes Circulation 1999, 99:3227-3233.
-
7Schwarts GG, Olsson AG, Ezekowitz MD, et al Effects of atorvastatin On early recurrent is chemic events in acute coronary syndromes.The MIRACL Study :a randomized controlled trial. JAMA,2001,285 (13) : 1711-1718.
-
8Thackray SDR, WitteKKA, et al.Clinical trials update :highlights of the scientific sessions of the Ameri-can Heart Association year 2000: Val HEFT, COPERNICAS, MERITCIBIS.Ⅱ. BEST AMIOVIRT, V-MAC BREAKTHE HEAT , MIRACI , FLORIDA.VIVA and the first human Cardiac skeletal mascle muscle myoblast transfer for heart failure, Eur J Heart Fail 2001, 3(1): 117-124.
-
9Jick H,Zornberg GL, Jiek SS, et al.Statins and the risk of dementia,Lancet, 2000, 356 (9242) : 1627-1631
-
10Meier CR,Sehliengei RG, Kraenzlin ME,et al.HMC-COA reduetase inhibitors and the risk of & actures.JAMA, 2000, 283(24) : 3205-3210.
-
1徐杰,范维琥.抗血小板聚集药在冠心病防治中的研究进展[J].中国临床药学杂志,2000,9(2):127-131. 被引量：1
-
2胡大一.他汀类药物的安全性问题[J].中国医师进修杂志（内科版）,2007,30(12):1-3. 被引量：11
-
3杨建云,彭水芳,于锋.防治冠心病新药——匹伐他汀[J].药学与临床研究,2011,19(6):534-537. 被引量：7
-
4王安才,成蓓.强化调脂治疗 加强冠心病防治[J].皖南医学院学报,2002,21(1):1-3. 被引量：7
-
5仝其广.浅谈调脂治疗中的几个问题[J].中国医院用药评价与分析,2003,3(1):45-46.
-
6丁荣晶.调脂药物的合理应用[J].中国社区医师,2011,27(8):12-12.
-
7袁凤贤,吴可光.降脂药对冠心病防治的重要意义[J].辽宁药物与临床,2002,5(1):6-8. 被引量：5
-
8徐国华,李庆,李良露.合理应用他汀类药物,促进血脂异常达标[J].中国医药导报,2009,6(2):158-159. 被引量：12
-
9熊健,张惠萍.浅谈调脂治疗在冠心病防治中的重要性[J].中华临床医药杂志（北京）,2003,4(24):96-96.
-
10胡大一,仝其广.中国胆固醇教育计划(CCEP)系列讲座(十二) 强化降脂 防治冠心病[J].中华医学信息导报,2005,20(19):14-14.
